AXSM - Kapitalisasi marang volume dodolan Axsome
The EV/Revenue multiple visualizes the market valuation of sales, where 8.80 shows the current value of the metric. The Axsome Therapeutics (AXSM) model is scalable: the launch of unique drugs ensures global distribution with high margins. The strategy is based on the repurposing of molecules for CNS treatment, creating pricing power. Axsome Therapeutics (AXSM) is currently expanding its presence in the migraine and depression segments, increasing patient flow.
Rincian analitis perusahaan Axsome Therapeutics Inc (AXSM)
- rega saham lan konsensus proyeksi valuasi:
- statistik kapitalisasi pasar:
- informasi kapitalisasi buku:
- statistik kawajiban utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi Axsome Therapeutics|AXSM - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Axsome Corp|AXSM - Utang perusahaan|Rasio utang-utang marang kapitalisasi buku Axsome Therapeutics Inc|AXSM - Utang jangka dawa perusahaan|Utang jangka cendhak Axsome Therapeutics|Rasio cepet axsome.com
- informasi bathi lan kelipatan valuasi:
AXSM - Penghasilan resik|Bathi resik mangsa ngarep Axsome Therapeutics|AXSM - Pangali P/E|Kapitalisasi marang proyeksi bathi Axsome|AXSM - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Axsome Therapeutics Inc|AXSM - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone patang kuartal pungkasan Axsome Therapeutics|AXSM - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan axsome.com|AXSM - Wutah bathi resik saben saham ing taun iki|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep Axsome Therapeutics
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:axsome.com - AXSM
Reliable distribution of neurological drugs through specialized climate-controlled channels ensures steady revenue growth for Axsome Therapeutics (AXSM). The current P/S valuation, reflecting the ratio of market capitalization to annual sales volume, allows for a comparison of business value against actual cash flows, helping investors determine the extent of asset overvaluation and balance potential returns against the risks of a late entry.
Perusahaan pesaing
BIIB (biogen.com) - Rasio kapitalisasi pasar marang pendapatan|Neurocrine Biosciences, Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan RGC (Regencell Bioscience Ltd)|ACADIA Pharmaceuticals Inc - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan XENE (Xenon Corp)|VKTX: Multiplikator P/S|Rega marang dodolan supernus.com (SUPN)|Rasio rega marang pendapatan Catalyst Pharmaceuticals, Inc.|DNLI: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S HRMY|Multiplikator P/S Biohaven Corp (BHVN)|Rasio rega marang pendapatan Amylyx Pharmaceuticals AMLX|TRVI (trevitherapeutics.com) - Rasio rega marang dodolan|Praxis Precision Medicines, Inc. - Multiplikator P/S|Rega marang dodolan Anavex|CBLL (CeriBell Corp) - Kapitalisasi marang pendapatan|Prothena Corp (PRTA) - Multiplikator P/S|Kapitalisasi marang pendapatan ALEC|ANNX (annexonbio.com) - Kapitalisasi marang volume dodolan|Multiplikator P/S OMER|Koefisien rega marang pendapatan Neurogene Inc|Multiplikator P/S ACIU (AC Immune Corp)|VYGR - Kapitalisasi marang pendapatan|NMRA - Rasio rega marang pendapatan|Koefisien rega marang pendapatan scilexholding.com SCLX|TVGN: Multiplikator P/S|Alpha Cognition Inc. (ACOG) - Multiplikator P/S|Kapitalisasi marang pendapatan CGTX|Rasio kapitalisasi marang pendapatan IKT (Inhibikase Pharma)|Rasio rega marang pendapatan Cassava Sciences, Inc. (SAVA)|Koefisien rega marang pendapatan assertiotx.com|Rasio rega marang pendapatan Coya Therapeutics COYA|VTGN - Kapitalisasi marang pendapatan|OVID - Rasio rega marang pendapatan|ABOS (Acumen Pharmaceuticals, Inc) - Rasio kapitalisasi marang pendapatan|CRVO: Multiplikator P/S|Rega marang dodolan Alterity Therapeutics Limited (ATHE)|Kapitalisasi marang pendapatan CLNN|Multiplikator P/S PepGen Corp|Rasio rega marang pendapatan Jupiter Neurosciences (JUNS)|RLMD (Relmada Corp) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Annovis Bio, Inc. ANVS|Grace Therapeutics Inc (GRCE) - Rega marang dodolan|Firefly Neuroscience - Multiplikator P/S|KLTO - Multiplikator P/S|NRSN (neurosense-tx.com) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan RVPH|Rasio rega marang pendapatan MetaVia Inc.|neuraxis.com (NRXS) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Helius Medical (HSDT)|PASG - Rega marang dodolan|Rasio rega marang pendapatan Neuphoria Therapeutics NEUP|NERV - Kapitalisasi marang pendapatan|Athira Pharma, Inc. - Multiplikator P/S|Rega marang dodolan addextherapeutics.com|ALZN (alzamend.com) - Kapitalisasi marang pendapatan|Cyclerion Therapeutics, Inc. - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan PTIX|KTTA (Pasithea) - Kapitalisasi marang volume dodolan|Multiplikator P/S CRGT|ATXI (avenuetx.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S BCLI (BrainStorm Cell Therapeutics)|Cara Therapeutics Inc. (CARA) - Rega marang dodolan|CHRO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ELYM (Eliem Therapeutics)|ITCI: Multiplikator P/S|longboardpharma.com (LBPH) - Multiplikator P/S|Rasio rega marang pendapatan Marinus Pharmaceuticals, Inc.|NKGen Biotech Inc - Rasio rega marang dodolan|Multiplikator P/S NRBO|SAGE - Rega marang dodolan|Synaptogenix, Inc. - Kapitalisasi marang pendapatan|Multiplikator P/S trevena.com TRVN|VIGL: Kapitalisasi marang pendapatan|anewmeds.com - Kapitalisasi marang volume dodolan|CERE: Multiplikator P/S
